Skip to main content

Advertisement

SpringerLink
Log in

Five-year survival of Advanced Esophagogastric junction cancer with achieved by complete response preoperative S-1 + CDDP combination therapy and surgical resection

  • Case report
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

No clear consensus has been reached about the appropriate chemotherapy and/or surgery for esophagogastric junction cancer (EGJ) cancer, and no recommendations have been established. However, it is hoped that treatment of advanced gastric cancer with preoperative chemotherapy will be useful, in that it will result in down staging, increased resection rate due to tumor contraction, and avoidance of the need for multi-organ resection, and that it will thus contribute to improved prognosis. Numerous clinical studies have been carried out to date on treatment of advanced gastric cancer with multi-drug combination chemotherapy, with S-1, a pyrimidine-fluoride-based anti-tumor agent, as the principal component, and favorable results have been achieved. The present report is about a 66-year-old male who was diagnosed as having Siewert type II, stage IIIB EGJ cancer, and whose bulky tumor was treated with S-1 + CDDP (SP) preoperative chemotherapy and total gastrectomy, with the aim of achieving preoperative tumor contraction. The outcome was achievement of histological complete response, and the patient has now survived for 5 years since surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. HiMattew F, Thomas L et al (2013) Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Elsevier Inc. Semin Radiat Oncol 23:3–9

    Article  Google Scholar 

  2. Nakamura T, Ide H, Eguchi R et.al (2002) Adenocarcinoma of the esophagogastric junction: a summary of responses to a questionnaire on adenocarcinoma of the esophagus and the esophagogastric junction cancer in Japan. Diseases Esophagus 15, 219–225

    Article  CAS  Google Scholar 

  3. Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112

  4. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  CAS  Google Scholar 

  5. Sasako M, Sakuramoto S, katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393

    Article  CAS  PubMed  Google Scholar 

  6. Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma-2nd English edition-gastric. Cancer 1;10–24

    CAS  Google Scholar 

  7. Christoph S, Stephan G, Florian L et al (2010)Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol 28(35):5210–5218

    Article  Google Scholar 

  8. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20

    Article  CAS  PubMed  Google Scholar 

  9. Yoshikawa T, Tanabe K, Nishikawa K et al (2014) Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol 21(1):213–219

    Article  PubMed  Google Scholar 

  10. Iwasaki Y, Sasako M, Yamamoto S et al (2013) Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol 107:741–745

    Article  CAS  PubMed  Google Scholar 

  11. Koizumi W, Narahara H, Hara T et al (2009) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastrointestinal and Hepatobiliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan

    Yoshikazu Kanazawa, Itsuo Fujita, Daisuke Kakinuma, Hitoshi Kanno, Hiroki Arai, Takeshi Matsutani, Nobutoshi Hagiwara, Tsutomu Nomura, Shunji Kato & Eiji Uchida

  2. Department of Pathology, Nippon Medical School, Tokyo, Japan

    Zenya Naito

Authors
  1. Yoshikazu Kanazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Itsuo Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daisuke Kakinuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hitoshi Kanno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroki Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takeshi Matsutani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobutoshi Hagiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tsutomu Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shunji Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zenya Naito
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Eiji Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshikazu Kanazawa.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical.

Informed consent

Informed consent was obtained from the patient for the publication of this case presentation and accompanying images.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kanazawa, Y., Fujita, I., Kakinuma, D. et al. Five-year survival of Advanced Esophagogastric junction cancer with achieved by complete response preoperative S-1 + CDDP combination therapy and surgical resection. Int Canc Conf J 6, 60–64 (2017). https://doi.org/10.1007/s13691-017-0279-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-017-0279-9

Keywords

Search

Navigation